Billionaire activist investor Carl Icahn is planning to nominate himself and three others to the board of embattled biotechnology company Genzyme.

Intelligence, benchmarking, and certification for risk and compliance leaders, from the institution setting the standard since 1922.
Billionaire activist investor Carl Icahn is planning to nominate himself and three others to the board of embattled biotechnology company Genzyme.
Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,... More by Jaclyn Jaeger
We'll send a verification code to %EMAIL%.